Genmab/AbbVie Look To Encroach On Roche’s Turf With Epkinly Follicular Lymphoma Results

 
• By Alaric DeArment

The companies unveiled results showing a high overall response rate from the anti-CD20xCD3 bispecific as competition heats up between various players in the space.

• Source: Shutterstock

More from Immuno-oncology

More from Anticancer